Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform
Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform
02/12/24, 3:15 AM
Location
san carlosMoney raised
$30 million
Industry
therapeutics
biotechnology
Round Type
series a
Attovia Therapeutics announced the closing of the $30 million second tranche of its previously reported $60 million Series A financing. The funding will support building immunology and inflammation pipeline, advancing lead programs into the clinic and ongoing development of the Attobody™ platform.
Company Info
Location
san carlos, california, united states
Additional Info
Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY™, our proprietary biologics platform, to generate first-in-class and best-in-class bispecifics and multispecifics.